Clinical studies have demonstrated the potential of c-Met inhibitors as a novel form of targeted therapy, as an investigation into primary breast cancer patients revealed that elevated phosphorylated c-Met expression (pY1234/5) was found to be associated with TNBC patients [39]. Here, MET is linked to breast carcinoma.